UBS Group
TVRD

UBS Group’s Tvardi Therapeutics TVRD Stock Holding History

UBS Group’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,175
Closed -$1.21M – 8058
2017
Q2 		$1.21M Buy
+2,175
New +$1.38M ﹤0.01% 3451

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

UBS Group's TVRD Position: Q1 2026 in Review

UBS Group increased its Tvardi Therapeutics (TVRD) stake by 42% in Q1 2026, buying an estimated $58.4K and bringing the position to 50,454 shares worth $160K. The position accounts for ﹤0.01% of the portfolio, ranked #6759.

UBS Group first reported a position in TVRD in Q4 2014 and has held it in 46 quarters since. The position peaked at $2.64M in Q4 2018. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

  • UBS Group held 50,454 shares of Tvardi Therapeutics worth $160K as of Q1 2026.
  • UBS Group bought 14,899 Tvardi Therapeutics shares in Q1 2026, an estimated $58.4K.
  • Tvardi Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6759 holding.
  • UBS Group first reported a position in Tvardi Therapeutics in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Tvardi Therapeutics position peaked at $2.64M in Q4 2018.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.